Hence, our study has identified Survivin as a potential novel molecular target of Nef in PCa cells, which needs further validation in order to develop Nef as a clinically viable antitumor drug due to the differential expression of Survivin in malignant versus normal cells. The gene discussed is BIRC5; the disease is posterior cortical atrophy.